09:54 AM EST - Resverlogix Corp. : Announces that its investigational epigenetic therapeutic apabetalone met the primary endpoint in an investigator led pulmonary arterial hypertension (PAH) pilot study, successfully completing the APPROACH-p trial (Apabetalone for Pulmonary Arterial Hypertension: A Pilot Clinical Study). Resverlogix Corp.
shares T.RVX are trading unchanged at $3.00.
